AMH fertility test use rises 13‑fold in Australia, study says it can't predict natural pregnancy

Increasing numbers of Australian women are turning to the anti‑Müllerian hormone (AMH) blood test to gauge their fertility, yet new research indicates the test may not deliver the insights many expect. A study led by Flinders University and published in the *Australian and New Zealand Journal of Obstetrics and Gynaecology* found that general practitioners’ requests for AMH testing surged more than thirteen‑fold between 2011 and 2021. The authors note that, despite its widespread use, the test has no proven ability to predict whether a woman will conceive naturally—either now or in the future.

The research highlights a growing disconnect between clinical practice and evidence. While AMH levels can reflect ovarian reserve, the study’s authors argue that this metric alone does not translate into reliable fertility outcomes. They point to accumulating data that shows a weak correlation between AMH concentrations and natural conception rates, suggesting that the test’s predictive value is limited. The findings come at a time when many patients seek early reassurance about their reproductive potential, and the study underscores the need for clearer guidance on the appropriate use of AMH testing.

In light of these results, clinicians and patients alike may need to reassess the role of AMH testing in fertility planning. The study calls for updated counseling practices that emphasize the test’s limitations and encourage a more comprehensive assessment of reproductive health. As demand for AMH testing continues to rise, the medical community faces the challenge of aligning patient expectations with the evidence base.